

Global
network

Creation of
value

Flexible
capital

Strategic and
operating
expertise

Investor
Growth Capital
Europe

Investor Growth Capital Europe

Located in Stockholm, Investor Growth Capital Europe is the European arm of Investor Growth Capital, a venture capital organization with units in Europe, the U.S. and Asia.

Investor Growth Capital Europe is a committed investor with a long-term investment philosophy, staying power and value-creating agendas.

We always work closely with the management of our holdings to develop their growth strategy, business and organization. Our holdings directly benefit from the experience and analytical skills of our investment professionals and the technical and managerial expertise of our senior advisers.

Today, we primarily invest in expansion-stage companies in the life sciences and technology fields.

Investment criteria

Our investment horizon is normally between three and seven years, with investments initially ranging between EUR 3 and 20 million. Follow-on investments are made as appropriate.

We prefer to invest in companies with innovative technologies and products, and with a scalable business model offering a sustainable competitive advantage.

Investment candidates typically have proven market potential and some level of established customer base or clinical evidence. They are driven by strong and highly motivated management teams working in strategic partnership with us.

Investment sectors

We invest in companies and technologies that have successfully passed their first stages of development. Our investment candidates are typically found within the following subsectors:

Life Sciences

- Medical devices
- Pharmaceuticals and biocentrals
- Diagnostics
- Healthcare services and life science tools

Technology

- Software
- Telecom and datacom equipment
- Nanotechnology and materials
- Clean technologies



We always work closely with the management of our holdings to develop their growth strategy, business and organization.

Since the start of operations, Investor Growth Capital Europe has invested over USD 500 million in more than 80 companies in the life sciences and technology sectors in Northern Europe.

Investor Growth Capital and Investor AB

Investor Growth Capital

Investor Growth Capital Europe is part of Investor Growth Capital, the wholly-owned venture capital arm of Investor AB.

Investor Growth Capital was formed by Investor in the mid-1990s to invest in high-quality, growth-oriented companies in the healthcare and technology industries.

Investor Growth Capital is organized in three units – Investor Growth Capital Asia, Investor Growth Capital Europe and Investor Growth Capital US – with offices in Stockholm, New York, Menlo Park (California), Hong Kong, Beijing, Tokyo and Amsterdam. All Investor Growth Capital offices are staffed with local employees with substantial knowledge of regional markets and companies.

Today, the Investor Growth Capital organization consists of more than 30 investment professionals and advisers around the world.

In total, Investor Growth Capital has approximately 100 investments in the technology and healthcare sectors.

*For more information please visit:
www.investorgrowthcapital.com*

Investor AB

Investor AB is the largest industrial holding company in the Nordic region. Investor is publicly traded and listed on the Stockholm Stock Exchange. The company is a leading shareholder and value creator in a number of major multinational companies.

Within Investor, Investor Growth Capital and EQT, which is partially owned by Investor, form the Private Equity Investments business area. EQT is a leading private equity group and buyout fund with operations in Northern Europe and Greater China. Private equity is an important way for Investor to create attractive proprietary returns for its shareholders.

Investor also operates through the business areas Core Investments and Operating Investments. The Core Investments are global, public companies in which Investor has a clear ownership role with significant influence. Investor has ten core investments today: ABB, AstraZeneca, Atlas Copco, Electrolux, Ericsson, Husqvarna, OMX, Saab, Scania and SEB.

Investor's Operating Investments include Gambro, a global medical technology company, 100 percent acquired and delisted by Investor and EQT in June 2006, and the 3G mobile telecom operator 3 Scandinavia, which was created in partnership with Hutchison Whampoa of Hong Kong.

*For more information please visit:
www.investorab.com*

Investor Growth Capital was formed by Investor in the mid-1990s to invest in high-quality, growth-oriented companies in the healthcare and technology industries.

Investor AB is the largest industrial holding company in the Nordic region.



How we build value in companies

We provide strategic, operating and financial expertise

Investor Growth Capital Europe commits itself to portfolio companies primarily through our work on their boards. This commitment goes beyond simple monitoring because we actively help you develop your corporate strategy, manage operational challenges, select executive team members, and raise debt and equity capital, all to create sustainable value in the marketplace. We are long-term in vision but very active in our short-term follow-up and ownership role.

Access to a global relationship network

Our portfolio holdings also gain valuable access to Investor Growth Capital's international network and business experience. This includes our network of investment professionals in the Investor Growth Capital U.S. and Investor Growth Capital Asia organizations, as well as Investor AB's global relationship network of people and businesses.

Investor Growth Capital Europe also has an extensive access to investment banks, commercial banks and other lenders, law firms, accounting firms, executive recruiting firms, industry research houses, and other venture capital firms. The unique international dimension to Investor Growth Capital Europe makes us a highly competitive partner when companies want to expand internationally.

Offering patient and flexible capital

Investor Growth Capital is structured as an evergreen capital pool. Unlike most venture capital firms, we do not have a finite fund life. This longer-term perspective and flexibility enables us to support a company through several phases of development. We can also avoid the usual pressure of seeking liquidity because of the requirements of external limited partners. We are open to both private and public investments.

Long experience of building companies

Having worked with a very large number of portfolio companies, Investor Growth Capital Europe's investment professionals have years of operational and venture capital experience from investing in growth companies throughout their life cycle.

The unique international dimension to Investor Growth Capital Europe makes us a highly competitive partner when companies want to expand internationally.

Our longer-term perspective and ownership approach enables us to very actively support a company through several phases of its development.



Team

Investment professionals



Thomas Eklund
Managing Director

Thomas Eklund is Managing Director and Co-Head of Investor Growth Capital Europe in Stockholm. From June 2000 to September 2002,

Thomas was an Investment Director of ABN Amro Capital Investments, where

his responsibilities included investment processing of expansion capital and MBO transactions in the Nordic region.

Before joining ABN Amro, Thomas was employed at Handelsbanken Securities Corporate Finance, where he was Vice President responsible for the healthcare group until he left in 2000.

Thomas holds an M.B.A. from the Stockholm School of Economics.



Karl Swartling
Managing Director

Karl Swartling is Managing Director and Co-Head of Investor Growth Capital Europe in Stockholm. He joined the company in January 2004.

Before joining our Stockholm office, Karl spent 15 years with the McKinsey & Co. consulting firm. During his last seven years at McKinsey, Karl was a partner in the company's Stockholm office. As a consultant, he focused on two main industry sectors: life sciences and industry. Karl also led McKinsey's Scandinavian Life Sciences Practice for a period of five years.

Karl holds an M.B.A. from the Stockholm School of Economics.



Jakob Lindberg
Vice President

Jakob Lindberg joined Investor Growth Capital Europe in the beginning of 2006 after working as a consultant for one year. Jakob focuses on investments in life sciences.

Prior to joining Investor Growth Capital Europe, Jakob worked at McKinsey & Co. and was co-founder and CEO of Collectricon AB, a Swedish company developing functional cell-based screening devices for drug discovery.

He is a licensed Swedish physician with an M.D. degree from Karolinska Institute and a B.A. in Finance from Stockholm University.



Mikael Johnsson
Vice President

Mikael joined Investor Growth Capital in 2000 where he focuses on technology sector investments. Before joining Investor Growth Capital Europe, Mikael was a management consultant at KPMG, delivering strategic IT advisory services to small

and large clients in various industries. Mikael also spent 18 months as an Investment Manager at b-business partners, a European venture capital company financed by Investor and a number of blue-chip industrial companies. Mikael holds an M. Sc. degree in Industrial Engineering and Management from the Linköping Institute of Technology in Sweden.



Anders Ösund
Vice President

Anders joined Investor Growth Capital Europe in 2001 and focuses on investments in the technology and medical devices sectors.

Before joining Investor Growth Capital Europe, Anders was an analyst at Investor AB, where he worked on strategic challenges and transactions for some of the company's core investments. Anders earned a M.Sc. degree in Applied Physics from the Royal Institute of Technology in Stockholm. He also holds an M.B.A. from the Stockholm School of Economics.



Joachim Werr
Vice President

Joachim Werr joined Investor Growth Capital Europe in Stockholm in January 2007.

Prior to joining IGC Europe, he was a practicing physician in the emergency room at Karolinska University Hospital in Stockholm (2004-2006).

Joachim also has a background as a consultant and engagement manager at McKinsey & Co.'s Stockholm office (2000-2004). At McKinsey, he was a member of the Pharma and Healthcare team focusing on strategy projects for clients in the life sciences field and for hospitals and global public health organizations.

Joachim studied medicine at Karolinska Institute (1991-1997) and became an M.D. and licensed physician in 2000. From 1997 to 2000, he was in Karolinska's Ph.D. program at the Department of Physiology and Pharmacology.

Team

Senior Advisers



Håkan Jansson

Håkan was a Managing Director of IGC Europe's Information Technology team in Stockholm between 2000 and 2005.

Prior to joining Investor, Håkan worked for Ericsson, a world-leading provider of telecom equipment and related services, from 1971 to 1998. At Ericsson, his

positions included Group Technical Director, Head of Public Telecommunications and Head of Mobile Phone Systems.

Håkan holds a M.Eng. degree from the Royal Institute of Technology in Stockholm.



Claes Wilhelmsson

Claes, a senior adviser at IGC Europe since 2002, has a solid background in the pharmaceuticals industry.

Claes joined Astra in 1985 as Medical Director for cardiovascular diseases. In 1991, Astra appointed him Executive Vice President of Research and Development.

Following the merger of Astra and Zeneca in 1999, Claes was appointed Executive Director, R&D, and served as a member of AstraZeneca's board. He retired from AstraZeneca in June 2002 and has published more than 270 papers on internal medicine and cardiology.

He holds M.D. and Ph.D. degrees from the Medical Faculty at the University of Gothenburg in Sweden.



Jan Stenberg

Jan Stenberg has a long career in leading executive positions in Ericsson. He was Executive Vice President of Ericsson when he left the company to become CEO of Scandinavian Airline Systems (SAS). He retired from SAS in 2001.



Staffan Josephson

As a senior adviser at IGC Europe, Staffan evaluates new investments and recommends new investments in the pharmaceuticals, biotechnology and medicinal technology fields.

Staffan joined IGC Europe in 1999. His 18 years of industry experience includes

acting as Head of Pharmacia BioScience Center and Vice President of Corporate R&D, Head of Preclinical R&D and Vice President (Biopharmaceuticals), Pharmacia AB, and Head of Operations, Planning and Development, Pharmacia & Upjohn. Staffan is currently Secretary General of the Heart-Lung Foundation in Sweden, a fund donating money for preclinical and clinical research on heart and lung diseases. Staffan holds a Ph.D. in Organicchemistry at the University of Stockholm where he is also a Professor



Henrik Baltscheffsky

Henrik has been a senior adviser to IGC Europe since February 2004. He also runs an advisory firm and has participated in select company startups as a partner to experienced entrepreneurs.

Between 1991 and 2003, Henrik was CEO of Salénia AB, a privately held investment company in Stockholm. Prior to that, Henrik spent three years in the U.S., and one year in Hong Kong, working on high-growth unlisted investments.

Henrik holds a M.Sc. degree in Economics from the Stockholm School of Economics.

Team

Support staff



Maria Thörnholm

Team Assistant

Maria joined Investor Growth Capital Europe in August 2007 as an assistant. Before joining Investor, Maria was a secretary at Advokatfirman Lindahl in Stockholm for 11 years. Maria has also worked for the Swedish venture capital company AB Traction.



Lena Kling-Lindahl

Controller

Lena joined Investor Growth Capital Europe in January 2000 after working for two years within Investor AB's Finance Department.

Lena works with both IT and healthcare investments in the Investor Growth Capital

Europe portfolio. Prior to joining the company, Lena worked at the Finance Department at the Wallenius shipping company and at the Stockholm office of Mercuri International, a company specializing in sales performance consulting.

Lena received her M.B.A. degree from the Stockholm School of Economics.

Aerocrine

Registered Office:

Solna, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

1999

Serving on the Board:

Karl Swartling

About Aerocrine

Aerocrine supplies instruments for nitric oxide (NO) measurements, a biological marker for airway inflammation. Measuring NO levels offers strong clinical benefits when diagnosing, monitoring and predicting exacerbations for asthma patients. Anti-inflammatory therapy is crucial to asthma treatment and a technique to measure inflammation non-invasively improves patient care. Aerocrine's products are world-leading for the routine measurement of the underlying inflammation in asthma. Aerocrine supplies the only products in this field with FDA approval. A hand-held device (NioxMino) has been launched, enabling much broader clinical use. The company was founded in 1997 by scientists from the Karolinska Institute in Sweden.

For more information visit

www.aerocrine.com

Affibody

Registered Office:

Bromma, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2000

Serving on the Board:

Karl Swartling

About Affibody

Affibody's vision is to be a leading player in the emerging field of personalized medicine within oncology, and a preferred partner and provider of high-quality biotechnology products. Affibody uses innovative protein-engineering technologies for the development of affinity ligands. Based on its proprietary technology platform, Affibody is developing a unique oncology pipeline, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics.

For more information visit

www.affibody.com



AirPlusTV

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

Media

Investment Year:

2008

Serving on the Board:

Karl Swartling

Mikael Johnsson

About AirPlusTV

AirPlusTV, headquartered in Stockholm, is a Swedish holding company set up to establish and launch Digital Terrestrial Television (DTT) operations in several markets with a focus on Western Europe.

For more information visit

www.airplustv.com

Applied Sensor

Registered Office:

Reutlingen, GERMANY

Listed:

Unlisted

Sector:

Technology

Subsector:

Semiconductors

Investment Year:

1997

Serving on the Board:

Håkan Jansson

About Applied Sensor

Applied Sensor develops and markets gas sensor components and systems for high-volume applications, such as air quality control applications for the automotive, industrial and residential markets. Applied Sensor is located in Linköping, Sweden, Reutlingen, Germany, and in New Jersey in the U.S.

For more information visit

www.appliedsensor.com



Atlas Antibodies

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2006

Serving on the Board:

Mikael Johnson

Karl Swartling

About Atlas Antibodies

Atlas Antibodies develops and commercializes novel antibodies for research purposes. The company also develops proprietary diagnostic and/or therapeutic applications.

For more information visit

www.atlasantibodies.com

Biotage

Registered Office:

Uppsala, SWEDEN

Listed:

Listed

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2003

Serving on the Board:

Thomas Eklund

About Biotage

Biotage manufactures and sells instruments for chemical analysis to improve drug discovery and development processes. The company's instruments increase the knowledge of the genetic makeup by providing complete solutions for medicinal chemistry research and applied genetic analysis.

For more information visit

www.biotage.com



Cambio

Registered Office:

Linköping, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Healthcare Services

Investment Year:

2006

Serving on the Board:

Karl Swartling

Mikael Johnsson

About Cambio

Cambio develops open healthcare administration systems with high flexibility and functionality. The company is aiming for safer and more reliable healthcare based upon relevant information being available for decisions, easy cooperation between healthcare units, relief from time-wasting routine work and the possibility of continuous IT development on terms that healthcare providers decide themselves.

For more information visit

www.cambio.se

Carmel Pharma

Registered Office:

Göteborg, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

1997

Serving on the Board:

Thomas Eklund

About Carmel Pharma

Carmel Pharma sells and manufactures the PhaSeal drug handling system for hospitals. PhaSeal is a closed system for handling antibiotics and cytostatic drugs which minimizes the leakage and spread of aerosols into the work environment, allowing more efficient handling near the patient.

For more information visit

www.carmelpharma.se



Cellectricon

Registered Office:

Göteborg, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2002

Serving on the Board:

Karl Swartling

About Cellectricon

Cellectricon develops and sells platforms for cell-based drug discovery based on unique competences in microfabrication, microfluidics, biosensors and cell biology. Live cellular analysis enables researchers to monitor drug candidate efficacy on a real-time basis as the drug enters the cell and alters its function. Cellectricon's first products are used today by the vast majority of the leading players in the pharmaceutical industry.

For more information

www.cellectricon.se

Doxa

Registered Office:

Uppsala, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

2005

Serving on the Board:

Karl Swartling

Anders Ösund

About Doxa

Doxa is a materials company founded in 1987 and based in Uppsala, Sweden. Doxa develops and commercializes bioactive materials for dental and bone replacement applications.

Doxa's non-resolvable bone material is currently in clinical trials.

For more information visit

www.doxa.se



Global Health Partner

Registered Office:

Göteborg, SWEDEN

Listed:

Listed, AIM

Sector:

Healthcare

Subsector:

Healthcare Services

Investment Year:

2007

Serving on the Board:

Joachim Werr
Karl Swartling

About Global Health Partner

Global Health Partner is a focused health care provider company operating in the areas of spine surgery, orthopedics/sports medicine, bariatric surgery and dental implants.

For more information visit

www.globalhealthpartner.se

Gyros

Registered Office:

Uppsala, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2000

Serving on the Board:

Håkan Jansson

About Gyros

Gyros has developed lab-on-a-chip microlaboratories for use in protein analysis within research, drug discovery and development applications, and in vitro diagnostics for medical applications.

A Gyrolab microlaboratory provides simple-to-use, precise solutions for processing hundreds of samples in parallel to generate more information from less samples.

For more information visit

www.gyros.se



Heartscape Technologies

Registered Office:

Columbia, MD, USA

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

2007

Serving on the Board:

Joachim Werr
Thomas Eklund

About Heartscape Technologies

Heartscape Technologies, Inc. is engaged in the development and marketing of the PRIME ECG® System (PRIME), a breakthrough medical device that is designed to allow more accurate and rapid diagnosis of heart attacks (acute myocardial infarction or AMI) and ischemia. PRIME is a patented, FDA approved product.

For more information visit
www.heartscape.com

Keybroker

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

Media

Investment Year:

2008

Serving on the Board:

Mikael Johnsson

About Keybroker

Keybroker delivers increased online sales for major advertisers through search advertising on the Internet (sponsored links on Google, MSN, Yahoo and other search engines). The company also develops advanced technology for large-scale campaign management and automated advertising processes.

For more information visit
www.keybroker.com



Mando

Registered Office:

Huddinge, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Healthcare Services

Investment Year:

2000

Serving on the Board:

Karl Swartling

About Mando

AB Mando has developed and commercialized a treatment program for eating disorders such as anorexia and bulimia. The treatment procedure combines behavioral treatment in combination with a specific device in order to train the patients to gradually normalize their eating pattern. The clinical outcome is unique, with respect to outstanding success rates and low relapse rates. Mando currently runs clinics in Sweden, the Netherlands, Australia and the United States. A treatment concept for obesity is currently being tested in large clinical trials.

For more information visit

www.mando.se

Memira

Registered Office:

Uppsala, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Healthcare Services

Investment Year:

2007

Serving on the Board:

Anders Ösund

Thomas Eklund

About Memira

Memira is the Nordic countries largest chain for refractive laser surgery. Offering safe and quick operations for correcting near, long sightedness and other eye surgeries for correcting imperfekt vision.

For more information visit

www.memira.se



Neoventa

Registered Office:

Möln dal, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

2006

Serving on the Board:

Thomas Eklund

About Neoventa

Neoventa Medical AB is a medtech company developing monitoring and management tools for improved perinatal healthcare.

For more information visit

www.neoventa.se

NeuroNova

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Pharmaceuticals

Investment Year:

2000

Serving on the Board:

Karl Swartling

Staffan Josephson

About NeuroNova

NeuroNova AB is a leader in therapeutic neurogenesis. The company researches and develops innovative therapies for disorders of the central nervous system, exploiting discoveries about regrowth and know-how of adult neuronal stem cells in the brain and neurogenesis. The objective of the company's therapies is to treat neurodegenerative diseases, such as Parkinson's disease, ALS and Huntington's disease.

For more information visit

www.neuronova.com



Projectplace

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

IT Services

Investment Year:

2000

Serving on the Board:

Henrik Baltscheffsky

About Projectplace

Projectplace International is an application service provider (ASP) for project management and collaboration over the Internet.

Projectplace was founded in 1998. The company is headquartered in Stockholm and has sales offices in Norway, the Netherlands, the U.K. and Germany.

Projectplace offers professional web service that project participants can conveniently use to collaborate regardless of their physical location. Projectplace.com/projektplatsen.se lets customers share documents and files, schedule meetings, do project scheduling and other project management-related tasks.

For more information visit

www.projectplace.com

SamSari

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

IT Services

Investment Year:

2000

Serving on the Board:

Henrik Baltscheffsky

Mikael Johnsson

About SamSari

SamSari is a Swedish consulting company that helps companies and organizations to realize their strategies. SamSari therefore specializes in the final implementation stage of change projects.

Customers include large international companies and organizations. SamSari works according to its own proprietary process called the SamSari Methodology™, which is based on interaction, cooperation and communication between individuals that accelerates knowledge creation and builds a common platform for change behavior. Since implementing change must also be fun and stimulating, the methodology is based on a mix of activities specially designed for the members of a group.

For more information visit

www.samsari.com



SciBase

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

2006

Serving on the Board:

Thomas Eklund

Jakob Lindberg

About SciBase

SciBase AB develops and provides technology and knowledge for non-invasive detection and monitoring of skin tissue alterations, in particular for skin cancer.

For more information visit

www.scibase.se

Sidec

Registered Office:

Kista (Stockholm), SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Diagnostics

Investment Year:

2007

Serving on the Board:

Jakob Lindberg

About Sidec

Sidec provides dramatic improvements in the development, protection and promotion of antibody and protein therapeutics. The company's protein tomography visualizes how proteins interact in-situ. Sidec provides its research partners with information to prioritize the most promising antibodies for development and expedite the drug approval process through conclusive proof of the molecular mechanism of action.

For more information visit

www.sidec.com



Stick Tech

Registered Office:

Turku, FINLAND

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Medical Devices

Investment Year:

1999

Serving on the Board:

Håkan Jansson

About Stick Tech

Stick Tech develops, manufactures and markets fiber-reinforced composites for dental reinforcements. Products are based on fiber reinforcement technology that is quick and cost-efficient. The technology is used in a number of applications, such as bridges, crowns and orthodontics.

Stick Tech's products complement other materials, such as metal.

For more information visit

www.sticktech.com

Swedish Orphan International

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Pharmaceuticals

Investment Year:

2004

Serving on the Board:

Thomas Eklund

About Swedish Orphan International

Swedish Orphan International (SOI) specializes in the development, marketing and distribution of pharmaceutical products, focusing on orphan drugs (niche products) with unmet medical needs that can be used in the treatment of rare disorders and life-threatening diseases.

SOI markets some 40 products, of which two are proprietary and the rest licensed from partners such as Chiron, Cephalon, Giliad, Shire and Actelion.

For more information visit

www.swedishorphan.com



Sörman

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

IT Services

Investment Year:

2000

Serving on the Board:

Anders Ösund
Karl Swartling

About Sörman

Sörman is a market-leading technology provider of Product Lifecycle Management ("PLM") information solutions for advanced products and systems.

For nearly 40 years, Sörman's differentiating factor has been its unrivalled knowledge of aftermarket information requirements from the manufacturing process of advanced technical products and systems.

The company's offering is structured around three types of solutions: services, systems and outsourcing partnerships.

For more information visit

www.sorman.com

Tobii

Registered Office:

Stockholm, SWEDEN

Listed:

Unlisted

Sector:

Technology

Subsector:

Technology hardware and software

Investment Year:

2007

Serving on the Board:

Anders Ösund

About Tobii

Tobii Technology is a fast growing the world leader in hardware and software solutions for eye tracking and eye control. With eye tracking a computer knows exactly where a person is looking, enabling computer control interfaces and a powerful behaviour analysis. Tobii has revolutionized eye tracking by making it plug-and-play, fully automatic and easy to use. Tobii's products are widely used within the scientific community and in commercial market research and usability as well as by disabled people as a primary way to communicate. Tobii also drives integration of eye tracking technology into a large number of other application areas. Potential markets range from gaming, automotive, consumer PC-interaction etc.

For more information visit

www.tobii.com



Åmic

Registered Office:

Uppsala, SWEDEN

Listed:

Unlisted

Sector:

Healthcare

Subsector:

Life Science Tools

Investment Year:

2002

Serving on the Board:

Jakob Lindberg

Thomas Eklund

About Åmic

Åmic has developed a diagnostic platform based on microfabrication technology with exceptional performance, particularly in point-of-care settings (bedside/ emergency room diagnostics). The first diagnostic product is currently under development. In addition, Åmic has two technology partnerships with global diagnostic players.

For more information visit

www.amic.com





Long-term value is created
by developing imaginative
business ideas.

And having the power to
implement them.

Investor Growth Capital Europe

Investor Growth Capital AB
SE-103 32 Stockholm, Sweden
Visiting address: Arsenalsgatan 8C
Phone: +46 8 614 1800
Fax: +46 8 614 1809

www.investorgrowthcapital.com